# EDGAR Filing Document

**Accession Number:** 0000771856
**File Stem:** 0001628280-26-004381
**Filing Date:** 2026-1
**Character Count:** 8171
**Document Hash:** a8a29d5571d0e89b63c02e2ecb2bdb83
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-004381.hdr.sgml**: 20260130

**ACCESSION NUMBER**: 0001628280-26-004381

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250716

**FILED AS OF DATE**: 20260130

**DATE AS OF CHANGE**: 20260130

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Brainin Robert Lawrence
- **CENTRAL INDEX KEY:** 0002088015

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11504
- **FILM NUMBER:** 26583191

**MAIL ADDRESS:**
- **STREET 1:** 241 BUCKMINSTER RD
- **CITY:** BROOKLINE
- **STATE:** MA
- **ZIP:** 02445
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CHAMPIONS ONCOLOGY, INC.
- **CENTRAL INDEX KEY:** 0000771856
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 521401755
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0430

**BUSINESS ADDRESS:**
- **STREET 1:** 855 N. WOLFE STREET
- **STREET 2:** SUITE 619
- **CITY:** BALTIMORE
- **STATE:** MD
- **ZIP:** 21205
- **BUSINESS PHONE:** 410-369-0365

**MAIL ADDRESS:**
- **STREET 1:** 855 N. WOLFE STREET
- **STREET 2:** SUITE 619
- **CITY:** BALTIMORE
- **STATE:** MD
- **ZIP:** 21205

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHAMPIONS BIOTECHNOLOGY, INC.
- **DATE OF NAME CHANGE:** 20070220

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHAMPIONS SPORTS INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INTERNATIONAL GROUP INC
- **DATE OF NAME CHANGE:** 19860319

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Brainin Robert Lawrence<br><sub>(Last) (First) (Middle)</sub><br>C/O CHAMPIONS ONCOLOGY, INC<br>ONE UNIVERSITY PLAZA, SUITE 307<br><sub>(Street)</sub><br>HACKENSACK, NJ 07601<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-07-16 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>CHAMPIONS ONCOLOGY, INC. [ CSBR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Option to purchase Common Stock | $7.80 | 2025-07-16 |  | A |  | 225000 |  | <sup>(1)</sup> | 2035-07-16 | Common Stock | 225000 | $7.80 | 299163 | D |  |
| Option to purchase Common Stock | $7.80 | 2025-07-16 |  | A |  | 62500 |  | <sup>(2)</sup> | 2035-07-16 | Common Stock | 62500 | $7.80 | 361663 | D |  |
| Option to purchase Common Stock | $7.80 | 2025-07-16 |  | A |  | 62500 |  | <sup>(3)</sup> | 2035-07-16 | Common Stock | 62500 | $7.80 | 424163 | D |  |
| Option to purchase Common Stock | $7.80 | 2025-07-16 |  | A |  | 150000 |  | <sup>(4)</sup> | 2035-07-16 | Common Stock | 150000 | $7.80 | 574163 | D |  |
| Option to purchase Common Stock | $7.80 | 2025-07-16 |  | A |  | 100000 |  | <sup>(5)</sup> | 2035-07-16 | Common Stock | 100000 | $7.80 | 674163 | D |  |
| Option to purchase Common Stock | $7.80 | 2025-07-16 |  | A |  | 100000 |  | <sup>(6)</sup> | 2035-07-16 | Common Stock | 100000 | $7.80 | 774163 | D |  |

---

### Footnotes:

(1) The options vest and become exercisable as follows: 25% will vest on the one-year anniversary of the grant date on July 16, 2026; the balance will vest ratably at a rate of 1/36th each month thereafter.

(2) The options will vest and be exercisable if the Company achieves EBITDA of $25 million over any consecutive four quarter period (based on the Company's fiscal year).

(3) The options will vest and be exercisable when $15 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year).

(4) The options will vest and be exercisable if (i) the Company achieves EBITDA of $35 million over any consecutive four quarter period  (based on the Company's fiscal year) or (ii) when $30 million of the Company's data revenue is recognized over any consecutive four quarter period (based on the Company's fiscal year).

(5) The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $16.00 Strike Price.

(6) The options will vest and be exercisable on the first date on which the average closing price (rounded to the nearest penny) of the Company's listed stock for the then previous forty five (45) calendar days is equal to or greater than the $24.00 Strike Price.

**Signature:** /s/ Robert L. Brainin  
**Date:** 2026-01-30

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**